drugset / Trial / NCT01001715
Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with vertebral fracture. Secondary objectives were: * to assess the safety and tolerability of REGN475/SAR164877 in patients with vertebral fracture pain; * to characterize the pharmacokinetic and immunogenicity profiles of REGN475/SAR164877 in this population.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasinumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.